Network-Directed Anti-Amyloid Immunotherapy via Transcranial Focused Ultrasound
Curated pathway from expert analysis
flowchart TD
A["Focused Ultrasound<br/>Blood-Brain Barrier Opening"]
B["Anti-Amyloid Antibody<br/>Enhanced Delivery"]
C["Network-Level Amyloid<br/>Clearance Achieved"]
D["Functional Connectivity<br/>Restoration"]
E["Transcranial Targeting<br/>Precision Delivery"]
F["AD Pathology Reduction<br/>at Network Scale"]
G["FUS as Amyloid<br/>Immunotherapy Adjuvant"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"enables"| B
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for NETWORK-DIRECTED yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for Network-Directed Anti-Amyloid Immunotherapy.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF network-directed transcranial focused ultrasound (tFUS) is applied to the default mode network in early Alzheimer's disease patients receiving standard anti-amyloid antibody therapy (e.g., lecanema | ≥15% reduction in DMN amyloid PET standardized uptake value ratio (SUVR) relative to baseline, with ≥10% differential reduction compared to non-targeted cortica | — no observation — | pending | 0.65 |
| IF network-directed tFUS preferentially enhances anti-amyloid antibody delivery across the blood-brain barrier in Alzheimer's disease patients, THEN cerebrospinal fluid (CSF) amyloid-beta 42/40 ratio | CSF Aβ42/40 ratio increase of ≥0.05 units in tFUS + immunotherapy group vs. ≥0.02 units in immunotherapy-only group (demonstrating enhanced amyloid clearance). | — no observation — | pending | 0.55 |